ABIONYX Pharma is Scaling up Its Operations After Securing the Resources Needed to Achieve Its Goals and Is Embarking on a New Cycle of Value Creation in the Treatment of Severe Inflammation and Sepsis

About this update from Abionyx Pharma Sa

TOULOUSE, France & FULLERTON, Calif., June 30, 2026--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma (FR0012616852 – ABNX – eligible for the PEA PME program), a next-generation biopharmaceutical company developing innovative therapies for sepsis and critical care based on a proprietary apoA-I-based technology platform, today provided an update on the Combined General Meeting held at the company's headquarters and the new phase of development beginning on June 30, 2026. At the Combined General Meeting, all resolutions presented by the Board of Directors were adopted. ABIONYX Pharma thanks all shareholders who were present, represented, or voted by mail for their commitment and support during this General Meeting. The minutes of the General Meeting, as well as the voting results by resolution, will be available on the Company's website in the "General Meetings" section. Having secured the necessary resources for the development of its priority programs through a recent strategic financing transaction, the Company is entering a phase in which value creation will rely primarily on clinical execution, the quality of the data generated, and the progressive monetization of its scientific platform. Financial Resources to Support All Strategic Objectives Following the success of its recently completed financing round, the Company has secured funding totaling up to €33 million. This strengthened financial position provides a solid foundation for pursuing all of the Company's strategic objectives and allows it to fully focus its resources on the development of its priority programs: A Strategy Fully Focused on Execution

View stock analysis, news, and events for Abionyx Pharma Sa